Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib Therapy
- 15 August 2002
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (7) , 539-540
- https://doi.org/10.1056/nejm200208153470719
Abstract
The tyrosine kinase inhibitor imatinib mesylate specifically inhibits the BCR-ABL kinase, and has shown promising results in phase 1 and 2 trials in patients with chronic myelogenous leukemia at various stages of the disease.1,2 We describe a patient in whom a complete molecular response was achieved with no evidence of BCR-ABL messenger RNA (mRNA) six months after treatment with imatinib began.Keywords
This publication has 6 references indexed in Scilit:
- Kinetics of BCR‐ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real‐time polymerase chain reactionEuropean Journal of Haematology, 2001
- Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsSeminars in Hematology, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Manifold-assisted Reverse Transcription-PCR with Real-Time Detection for Measurement of the BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia PatientsClinical Chemistry, 2000